Definium Therapeutics, Inc. closed its underwritten public offering of 20,588,236 common shares. The shares were priced at $34.00 per share. The offering was upsized from an initial $500 million target.
Underwriters fully exercised their option to purchase an additional 3,088,235 shares. Total gross proceeds reached approximately $805 million. Net proceeds totaled approximately $758 million.
Definium will use the funds for research and development of its product candidates. This includes preparing for the potential commercialization of the DT120 ODT program for psychiatric and neurological disorders.
The capital infusion strengthens the company's balance sheet as it advances late-stage assets. The offering closed on June 25, 2026.